WO2007050574A1 - Formulation comprising a drug of low water solubility and method of use thereof - Google Patents

Formulation comprising a drug of low water solubility and method of use thereof Download PDF

Info

Publication number
WO2007050574A1
WO2007050574A1 PCT/US2006/041419 US2006041419W WO2007050574A1 WO 2007050574 A1 WO2007050574 A1 WO 2007050574A1 US 2006041419 W US2006041419 W US 2006041419W WO 2007050574 A1 WO2007050574 A1 WO 2007050574A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
water solubility
low water
formulation
indazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/041419
Other languages
French (fr)
Inventor
John M. Lipari
Didier R. Lefebvre
Tzuchi R. Ju
Kennan C. Marsh
Geoff Zhang
Jayanthy Jayanth
Chetan P. Pujara
Howard S. Cheskin
Vitomir Vucenovic
Ping Tong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to CN2006800490659A priority Critical patent/CN101346128B/en
Priority to JP2008537868A priority patent/JP2009513642A/en
Priority to EP06817321A priority patent/EP1959926A1/en
Priority to CA002626579A priority patent/CA2626579A1/en
Publication of WO2007050574A1 publication Critical patent/WO2007050574A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A pharmaceutical composition comprises a drug-carrier system having a small-molecule drug of low water solubility, e.g., N [4 (3-amino-1H-indazol-4-yl)phenyl]-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), and (+)-1-(5-tert-butyl-l-y1)-3-( lH-indazol-4-yl)-urea (ABT-102), in solution in a substantially non-aqueous carrier that comprises at least one phospholipid and a pharmaceutically acceptable solubilizing agent. The drug-carrier system, when mixed with an aqueous phase, typically forms a non-gelling, substantially non-transparent liquid dispersion. The composition is suitable for administration by a suitable route, e.g., orally, to a subject in need thereof.

Description

Figure imgf000005_0001
Figure imgf000006_0001
Figure imgf000011_0001
Figure imgf000013_0001
Figure imgf000026_0001
Figure imgf000026_0002
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000029_0001
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000034_0001
Figure imgf000034_0002
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000037_0002
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000066_0001
Figure imgf000066_0002
Figure imgf000067_0001
Figure imgf000067_0002
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000069_0002
Figure imgf000069_0003
Figure imgf000070_0001

Claims

Figure imgf000072_0001
Figure imgf000074_0001
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000080_0001
Figure imgf000082_0001
PCT/US2006/041419 2005-10-25 2006-10-24 Formulation comprising a drug of low water solubility and method of use thereof Ceased WO2007050574A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN2006800490659A CN101346128B (en) 2005-10-25 2006-10-24 Formulation comprising drug of low water solubility and method of use thereof
JP2008537868A JP2009513642A (en) 2005-10-25 2006-10-24 Formulation containing drug with low water solubility and method of using the same
EP06817321A EP1959926A1 (en) 2005-10-25 2006-10-24 Formulation comprising a drug of low water solubility and method of use thereof
CA002626579A CA2626579A1 (en) 2005-10-25 2006-10-24 Formulation comprising a drug of low water solubility and method of use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72983405P 2005-10-25 2005-10-25
US60/729,834 2005-10-25
US84864906P 2006-09-28 2006-09-28
US60/848,649 2006-09-28

Publications (1)

Publication Number Publication Date
WO2007050574A1 true WO2007050574A1 (en) 2007-05-03

Family

ID=37808098

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/041419 Ceased WO2007050574A1 (en) 2005-10-25 2006-10-24 Formulation comprising a drug of low water solubility and method of use thereof

Country Status (6)

Country Link
US (1) US20070104780A1 (en)
EP (1) EP1959926A1 (en)
JP (1) JP2009513642A (en)
CN (1) CN101346128B (en)
CA (1) CA2626579A1 (en)
WO (1) WO2007050574A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2072044A1 (en) 2007-12-19 2009-06-24 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising a liquid or flowable core composition
WO2009050289A3 (en) * 2007-10-19 2010-03-25 Abbott Gmbh & Co. Kg Solid dispersion product containing n-aryl urea-based compound
WO2009050291A3 (en) * 2007-10-19 2010-04-08 Abbott Gmbh & Co. Kg Solid dispersion product of n-aryl urea-based drugs
US7943782B2 (en) 2007-10-19 2011-05-17 Abbott Laboratories Crystalline chemotherapeutic
US7947843B2 (en) 2007-10-19 2011-05-24 Abbott Laboratories Crystalline chemotherapeutic
US7960564B2 (en) 2007-10-19 2011-06-14 Abbott Laboratories Crystalline chemotherapeutic
US7994208B2 (en) 2007-10-19 2011-08-09 Abbott Laboratories Crystalline chemotherapeutic
US8759538B1 (en) 2013-06-13 2014-06-24 Abbvie Inc. Crystalline chemotherapeutic
EP2588081A4 (en) * 2010-06-29 2014-12-10 Verastem Inc Oral formulation of kinase inhibitors
US9505719B2 (en) 2010-06-30 2016-11-29 Verastem, Inc. Synthesis and use of kinase inhibitors
EP2861234B1 (en) 2012-06-18 2019-03-27 TherapeuticsMD, Inc. Progesterone formulations
WO2022074457A1 (en) * 2020-10-06 2022-04-14 Gabather Ab Lipid formulations of triazoloquinazolinone compounds
EP4518842A4 (en) * 2022-05-03 2026-04-15 7 Hills Pharma Inc Novel low molecular weight integrin receptor ligand agonist carrier compositions based on lipids, pharmaceutical integrin agonist adjuvant compositions theretherin and methods for their manufacture and use

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521510A (en) * 2005-12-23 2009-06-04 アルコン，インコーポレイテッド Pharmaceutical formulations for delivery of receptor tyrosine kinase inhibition (RTKI) compounds to the eye
DK2644194T3 (en) 2008-03-18 2017-07-03 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
BRPI0909185A2 (en) 2008-03-20 2015-08-25 Virun Inc Vitamin E derivative and its uses
PL2268160T3 (en) * 2008-03-20 2013-05-31 Virun Inc Emulsions including a peg-derivative of tocopherol
US8298607B2 (en) * 2008-05-15 2012-10-30 Abbott Cardiovascular Systems Inc. Method for electrostatic coating of a medical device
US8337931B2 (en) * 2008-06-23 2012-12-25 Virun, Inc. Compositions containing non-polar compounds
US20100075933A1 (en) * 2008-07-28 2010-03-25 Sunita Vijay Shelke Injectable compositions of vitamin d compounds
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
EP2432453A2 (en) 2009-05-20 2012-03-28 Ranbaxy Laboratories Limited Topical retinoid solutions
US10022348B2 (en) 2009-05-20 2018-07-17 Sun Pharmaceutical Industries Limited Topical solution of isotretinoin
WO2010134047A2 (en) * 2009-05-20 2010-11-25 Ranbaxy Laboratories Limited Liquid dosage forms of isotretinoin
TWI471321B (en) * 2009-06-08 2015-02-01 亞培公司 Oral pharmaceutical dosage form of BCL-2 group inhibitor
TWI532484B (en) * 2009-06-08 2016-05-11 艾伯維有限公司 Solid dispersions containing an apoptosis-promoting agent
US8927009B2 (en) * 2009-12-22 2015-01-06 Abbvie Inc. ABT-263 capsule
CA2792330C (en) * 2010-03-23 2017-01-03 Virun, Inc Nanoemulsion including a peg-derivative of vitamin e and a sucrose fatty acid ester
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
UA113500C2 (en) 2010-10-29 2017-02-10 MEL EXTRUSION SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
JP2014505054A (en) 2011-01-10 2014-02-27 セルジーン コーポレイション Cyclopropanecarboxylic acid {2-[(1S) -1- (3-ethoxy-4-methoxy-phenyl) -2-methanesulfonyl-ethyl] -3-oxo-2,3-dihydro-1H-isoindole-4 -Il} -amide oral dosage form
US10874635B2 (en) * 2011-10-21 2020-12-29 First Tech International Limited Tocotrienol compositions
US10874122B2 (en) 2012-02-10 2020-12-29 Virun, Inc. Beverage compositions containing non-polar compounds
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
US10016363B2 (en) 2014-09-18 2018-07-10 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
EP3388054A1 (en) * 2017-04-12 2018-10-17 Athenion AG Dispensing cap containing a solubilisate of a pharmaceutically active agent or dietary supplement
TWI721255B (en) * 2017-05-10 2021-03-11 大陸商思路迪（北京）醫藥科技有限公司 A compound with anticancer effect and its preparation method and application (1)
AU2018312349A1 (en) 2017-08-01 2020-02-06 Theravance Biopharma R&D Ip, Llc Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
TWI805601B (en) * 2017-08-11 2023-06-21 南韓商愛茉莉太平洋股份有限公司 Pharmaceutical composition and method for inhibiting the formation of crystals thereof
US10716774B1 (en) 2018-01-05 2020-07-21 Yale Pharmaceuticals LLC Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability
EP3511325A1 (en) * 2018-01-11 2019-07-17 MetrioPharm AG Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione
WO2020079706A1 (en) * 2018-10-15 2020-04-23 Cipla Limited Pharmaceutical formulation
CN113498352A (en) 2019-01-23 2021-10-12 施万生物制药研发Ip有限责任公司 Imidazo [1,5-A ] pyridines, 1,2, 4-triazolo [4,3-A ] pyridines and imidazo [1,5-A ] pyrazines as JAK inhibitors
EP3914234A4 (en) * 2019-01-25 2022-09-14 Shenzhen Pharmacin Co., Ltd. PHARMACEUTICAL COMPOSITIONS
KR102227966B1 (en) * 2019-06-26 2021-03-16 주식회사 엠이티라이프사이언스 Pharmaceutical formulation of Inactivated Polypeptide TRP

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068139A1 (en) * 2000-03-13 2001-09-20 Korea Institute Of Science And Technology Formulation solubilizing water-insoluble agents and preparation method thereof
WO2002085414A2 (en) * 2000-12-19 2002-10-31 The Board Of Regents Of The University Of Texas System Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity
WO2004002414A2 (en) * 2002-06-28 2004-01-08 Shire Laboratories Inc. Self-emulsifying formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability and/or reduced food effect
US20040254188A1 (en) * 2003-06-12 2004-12-16 Arthur Gomtsyan Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
WO2004113304A1 (en) * 2003-05-22 2004-12-29 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2005087194A1 (en) * 2004-03-10 2005-09-22 Schering Aktiengesellschaft Compositions comprising drospirenone molecularly dispersed

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3608455A1 (en) * 1986-03-14 1987-09-17 Nattermann A & Cie PRODUCTS CONTAINING PHOSPHOLIPID, THEIR PRODUCTION AND USE
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
JP2948111B2 (en) * 1994-09-16 1999-09-13 塩野義製薬株式会社 Oily composition for oral administration
GB9424902D0 (en) * 1994-12-09 1995-02-08 Cortecs Ltd Solubilisation Aids
DE19641437A1 (en) * 1996-10-08 1998-04-09 Basf Ag 1,3-bis (N-lactamyl) propanes and their pharmaceutical and cosmetic use
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
KR20030009416A (en) * 2000-04-04 2003-01-29 시오노기세이야쿠가부시키가이샤 Oily compositions containing highly fat-soluble drugs
JP4116436B2 (en) * 2000-12-14 2008-07-09 エフ．ホフマン−ラ ロシュ アーゲー Self-emulsifying lipid matrix (SELM)
US20040235892A1 (en) * 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
KR101138216B1 (en) * 2003-06-12 2012-09-05 아보트 러보러터리즈 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
EP1498123A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Emulsifying systems containing azetidine derivatives

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068139A1 (en) * 2000-03-13 2001-09-20 Korea Institute Of Science And Technology Formulation solubilizing water-insoluble agents and preparation method thereof
WO2002085414A2 (en) * 2000-12-19 2002-10-31 The Board Of Regents Of The University Of Texas System Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity
WO2004002414A2 (en) * 2002-06-28 2004-01-08 Shire Laboratories Inc. Self-emulsifying formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability and/or reduced food effect
WO2004113304A1 (en) * 2003-05-22 2004-12-29 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20040254188A1 (en) * 2003-06-12 2004-12-16 Arthur Gomtsyan Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
WO2005087194A1 (en) * 2004-03-10 2005-09-22 Schering Aktiengesellschaft Compositions comprising drospirenone molecularly dispersed

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994208B2 (en) 2007-10-19 2011-08-09 Abbott Laboratories Crystalline chemotherapeutic
US8486988B2 (en) 2007-10-19 2013-07-16 Abbvie Inc. Crystalline chemotherapeutic
WO2009050291A3 (en) * 2007-10-19 2010-04-08 Abbott Gmbh & Co. Kg Solid dispersion product of n-aryl urea-based drugs
JP2011500647A (en) * 2007-10-19 2011-01-06 アボット ゲーエムベーハー ウント カンパニー カーゲー Solid dispersion product containing N-arylurea compounds
JP2011500649A (en) * 2007-10-19 2011-01-06 アボット ゲーエムベーハー ウント カンパニー カーゲー Solid dispersion products of N-arylureas
US7943782B2 (en) 2007-10-19 2011-05-17 Abbott Laboratories Crystalline chemotherapeutic
US7947843B2 (en) 2007-10-19 2011-05-24 Abbott Laboratories Crystalline chemotherapeutic
US7960564B2 (en) 2007-10-19 2011-06-14 Abbott Laboratories Crystalline chemotherapeutic
WO2009050289A3 (en) * 2007-10-19 2010-03-25 Abbott Gmbh & Co. Kg Solid dispersion product containing n-aryl urea-based compound
EP2072044A1 (en) 2007-12-19 2009-06-24 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising a liquid or flowable core composition
EP2588081A4 (en) * 2010-06-29 2014-12-10 Verastem Inc Oral formulation of kinase inhibitors
US9375402B2 (en) 2010-06-29 2016-06-28 Verastem, Inc. Oral formulations of kinase inhibitors
US9505719B2 (en) 2010-06-30 2016-11-29 Verastem, Inc. Synthesis and use of kinase inhibitors
EP2861234B1 (en) 2012-06-18 2019-03-27 TherapeuticsMD, Inc. Progesterone formulations
US8759538B1 (en) 2013-06-13 2014-06-24 Abbvie Inc. Crystalline chemotherapeutic
WO2022074457A1 (en) * 2020-10-06 2022-04-14 Gabather Ab Lipid formulations of triazoloquinazolinone compounds
EP4518842A4 (en) * 2022-05-03 2026-04-15 7 Hills Pharma Inc Novel low molecular weight integrin receptor ligand agonist carrier compositions based on lipids, pharmaceutical integrin agonist adjuvant compositions theretherin and methods for their manufacture and use

Also Published As

Publication number Publication date
CA2626579A1 (en) 2007-05-03
EP1959926A1 (en) 2008-08-27
CN101346128B (en) 2013-10-02
US20070104780A1 (en) 2007-05-10
CN101346128A (en) 2009-01-14
JP2009513642A (en) 2009-04-02

Similar Documents

Publication Publication Date Title
WO2007050574A1 (en) Formulation comprising a drug of low water solubility and method of use thereof
IL164163A0 (en) Process for preparing a finely self-emulsifiable pharmaceutical composition
CO5580835A2 (en) NEW CYCLOSPORINE ANALOG FORMULATIONS
WO2003092590A3 (en) Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
DK2046292T3 (en) Formulations for benzimidazolylpyridyl ethers
CA2415010A1 (en) Propane-1,3-dione derivatives useful as gnrh receptor antagonist
JP2001525363A5 (en)
JP2005508981A5 (en)
MY135119A (en) Stabilized oral suspension formulation
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
TW200716202A (en) Pediatric formulation of topiramate
EP0900562B1 (en) Lavage solution for intestinal tract
NO20043001D0 (en) Pharmaceutical formulation comprising cyclosporine and its use
EE200200483A (en) New self-emulsifying drug delivery system
EP1993567A4 (en) Orally administrable gallium compositions and method of use
WO2007067593A3 (en) Self-emulsifyng formulations of cetp inhibitors
NO950134L (en) Formulations for orally administered pharmaceutical agents
JP2003128549A (en) Composition applicable to mucous membrane
JP2009029779A (en) Aqueous pharmaceutical composition containing levocabastine and/or salt thereof
JP2003128552A (en) Composition applicable to mucous
WO2005101982A2 (en) A stable ophthalmic composition
AU2009316624B2 (en) Pyrazolone Derivative Formulations
JP4512700B2 (en) Acyclovir-containing aqueous preparation
MX2024013509A (en) Novel lipid-based small molecule integrin receptor-ligand agonist adjuvants carrier compositions, integrin agonist adjuvant pharmaceutical compositions therefrom, and methods for making and using same
WO2023099638A1 (en) Ophthalmic pharmaceutical compositions containing a nitric oxide-releasing phosphodiesterase 5 inhibitor and method for the preparation thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680049065.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2626579

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008537868

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/005393

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006817321

Country of ref document: EP